Annual General Meeting 2024

At today´s Annual General Meeting of BRAIN Biotech, the shareholders approved all items on the agenda with a clear majority. This year, the Annual General Meeting was a face-to-face event.

In his speech to shareholders, CEO Adriaan Moelker said: "We now have the architecture, the employees, the technology, the customers and the products to further accelerate our economic success. I am confident that we will succeed in achieving our main targets: double-digit sales growth, EBITDA of 15 % +/- 5 percentage points and positive operating cash flow within our planning horizon of five years." In its first quarterly figures for the 2023/24 financial year, the company recently announced a quantitative guidance for the full year with turnover to rise to EUR 58 million to EUR 62 million.

Dr. Michael Majerus, Chairman of the Supervisory Board, emphasized: “I was very pleased to be able to hold my first Annual General Meeting as Chairman in the form of a face-to-face event in direct contact with the shareholders.” Majerus continued: “In the past financial year 2022/23, BRAIN Biotech achieved the best revenue and adjusted EBITDA figures since the company's IPO. On this basis, the Supervisory Board supports the measures taken by the Management Board to exploit the Group's diverse potential with the aim of further increasing revenues and earnings and achieving the communicated mid-term targets.”

→ See related press release.

Picture (from left to right): Dr. Michael Majerus (Chairman of the Supervisory Board), Adriaan Moelker (CEO) and Michael Schneiders (CFO) during the Annual General Meeting.